EUVIMEDEUVIMED entdecken
Crossref

Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study

Cassandra White iD, Christine Paul, Esther Liet, Dilshan Kalpage, David Mossman, Andrew Ziolkowski, Stephen Ackland iD, Rodney J Scott

Internal Medicine Journal · 2025

DOI: 10.1111/imj.16576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Cassandra White und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Neoplasms, Antineoplastic Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: University of Newcastle Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Implementing pharmacogenomic‐guided management in cancer patients equitably and effectively in a large population presents challenges. DPYD genotyping determines clinically significant variants of patients at increased risk of developing grade3–5 fluoropyrimidine (FP) toxicity. FP chemotherapies are prescribed for ~16,000 Australians with a 10%–40% grade3–4 toxicity incidence and 1% mortality. Variant carriers can have FP dosing adjusted to improve treatment tolerance without compromising anticancer effect. This strategy has not been formally adopted within Australia, despite widespread international standardisation.

Aim

This pilot study determined genotyping turnaround‐times (TAT) for 4 DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T and c.1236G>A/Haplotype B3) in Australian patients. Secondary objectives were identification of FP toxicities of DPYD variant carriers, and analysis of healthcare stakeholder perspectives, including enablers/barriers to implementation.

Methods

Genotyping was determined by Real‐Time Polymerase Chain Reaction. Qualitative data were determined through semi‐structured questionnaire.

Results

104 patients recruited over 24 months had a mean TAT of 7.2 days, 5.2 business days (range 1–30). Grade3–4 toxicity occurred in 9/16 DPYD variant carriers, including 2 ICU admissions and 1 death. Themes from 30 questionnaire respondents suggest that clinical environment and resources were fundamental barriers, and motivation to improve patient care was the predominant enabler of change.

Conclusion

DPYD genotyping is feasible for improving precision‐oncology for patients requiring FP chemotherapies. A TAT of 7 days is acceptable by both stakeholder respondents and national oncology clinician groups. This pilot study, although small, informs a large national project evaluating prospective DPYD genotyping and its impact on FP tolerability, patient safety and cost‐effectiveness in Australia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)NeoplasmsAntineoplastic AgentsHumansAustraliaPilot ProjectsMaleFeasibility StudiesMiddle AgedFemaleAgedGenotypeAdultFluorouracil

Stichwörter der Autor:innen

DPYDdihydropyrimidine dehydrogenasefluoropyrimidinegenotypingpharmacogenomics

Substanzen

Dihydrouracil Dehydrogenase (NADP)Antineoplastic AgentsFluorouracil

Autor:innen und Institutionen

  • College of Health, Medicine and Wellbeing, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales, Australia.
  • Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
  • Department of Molecular Genetics, Pathology North John Hunter Hospital, Newcastle, New South Wales, Australia.
  • College of Health, Medicine and Wellbeing, School of Biomedical Science and Pharmacy, University of Newcastle, Newcastle, New South Wales, Australia.

ORCID-Profile: Cassandra White, Stephen Ackland

Förderung

  • University of Newcastle Australia

Zitieren

APA

White, C., Paul, C., Liet, E., Kalpage, D., Mossman, D., Ziolkowski, A., Ackland, S., & Scott, R. J. (2025). Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study. Internal Medicine Journal. https://doi.org/10.1111/imj.16576

Vancouver

White C, Paul C, Liet E, Kalpage D, Mossman D, Ziolkowski A, et al. Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study. Internal Medicine Journal. 2025. doi:10.1111/imj.16576

BibTeX
@article{White2025,
  author = {White, Cassandra and Paul, Christine and Liet, Esther and Kalpage, Dilshan and Mossman, David and Ziolkowski, Andrew and Ackland, Stephen and Scott, Rodney J},
  title = {Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.16576}
}
Kostenlos starten →